Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Novo Nordisk (NYSE:NVO) has filed for U.S. approval of an oral ... The medication is an oral form of semaglutide, the same active ingredient in Wegovy and Ozempic, Novo’s high-profile injectable drugs ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

UnitedHealth stock is rising after declining for eight consecutive sessions, Applied Materials issues a disappointing revenue ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

Novo Nordisk has replaced CEO Lars Fruergaard Jorgensen amid competitive pressures in the obesity drug market. His exit comes ...

Wall Street stocks rose again Friday, adding to weekly gains fueled by deescalation of the China-US trade war and hopes for ...